DSMB recommends tenofovir gel trial continue

A Data and Safety Monitoring Board (DSMB) held a scheduled review of the CAPRISA 004 Tenofovir Gel Phase IIb trial on 27 July 2009.

This microbicide trial is assessing the safety and effectiveness of 1% tenofovir gel to prevent HIV infection in women in South Africa. It is a collaborative effort between the Centre for the AIDS Programme of Research in South Africa (CAPRISA) at the University of KwaZulu-Natal in Durban, South Africa, Family Health International, and CONRAD. The study is funded by USAID and the South Africa Department of Science and Technology through LIFElab in South Africa.

The DSMB congratulated the study team on trial conduct and recommended that the study continue.

Source: Professor Salim Abdool Karim, Director: CAPRISA, Durban, South Africa